微笑研究:研究早期类风湿性关节炎的长期甲状腺和伊古拉提莫德联合治疗
Fang Du1, Qing Dai1, Jialin Teng1
1Department of Rheumatology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai 200001, China.
Chinese medical journal
|July 26, 2024
概括
在类风湿性关节炎 (RA) 患者中,Iguratimod (IGU) 单疗法和组合疗法显示出较高的临床响应,与甲状腺素 (MTX) 单疗法相比. 在放射性进展方面,IGU可能有好处,建议它作为潜在的初始RA治疗.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 类风湿性关节炎 (RA) 是一种全身性自身免疫性疾病,导致慢性炎症和关节破坏.
- 伊古拉提莫德 (IGU) 是一种新型常规合成疾病修饰性抗风湿药物 (csDMARD),在中国和日本使用.
- 在RA患者中,IGU对放射性进展的长期影响尚未得到充分证实.
研究的目的:
- 为了研究IGU单疗法和IGU与甲醇 (MTX) 结合的疗效和安全性,与MTX单疗法对比.
- 为了评估对MTX-naive活跃RA患者放射性进展的长期影响.
主要方法:
- 这是一项为期52周的多中心,双盲,随机化,非劣势性临床试验,涉及911名以前没有使用MTX的RA患者.
- 患者被随机分配到MTX单疗法,IGU单疗法或IGU + MTX组合疗法.
- 主要终点包括ACR20反应和范德海德修改的夏普总分数 (vdH-mTSS) 的变化.
主要成果:
- 在52周的ACR20反应率为77.44% (IGU),77.05% (IGU+MTX) 和65.87% (MTX).
- 在ACR20反应方面,IGU单疗法与MTX单疗法无差,且优于MTX单疗法.
- 在ACR20响应方面,IGU + MTX比MTX更优越;在不良事件发生率上没有显著差异.
结论:
- 与MTX单疗法相比,IGU单疗法和IGU + MTX显示出更有利的临床反应.
- IGU可能在放射性进展方面提供好处,将其定位为活跃RA的潜在初始治疗选择.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
149
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
149
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
126
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
126
Pulmonary Tuberculosis V
177
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
177
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
110
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
110
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
Drugs for Treatment of Ulcerative Colitis in IBD
134
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
134


